The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Long and deep responses to CAR T-cell therapies in multiple myeloma
CAR T-cells seem to be taking the hematology world by storm. Here. Rakesh Popat, MD, PhD from the University College London, London, UK talks to us about the different approaches being taken in multiple myeloma, such as the novel CAR T-cell construct idecabtagene vicleucel (formerly bb2121), and a novel unnamed construct from Legend Biotech, both targeting the B-cell maturing antigen (BCMA). In the UK, Dr Rakesh’s group is working on an different approach to targeting BCMA, by using APRIL, a natural bi-specific binding molecule of BCMA and TACI. Despite the deep and durable responses to this type of immunotherapy, side effects are still present and should be monitored closely.
